Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam (Articolo in rivista)

Type
Label
  • Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam (Articolo in rivista) (literal)
Anno
  • 2006-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1016/j.amjmed.2005.08.042 (literal)
Alternative label
  • Addolorato G., Leggio L., Abenavoli L., Agabio R., Caputo F., Capristo E., Colombo G., Gessa G.L., Gasbarrini G (2006)
    Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam
    in The American journal of medicine
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Addolorato G., Leggio L., Abenavoli L., Agabio R., Caputo F., Capristo E., Colombo G., Gessa G.L., Gasbarrini G (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 119 (literal)
Rivista
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Institute of Internal Medicine, Catholic University of Rome, Rome, Italy; \"Bernard B. Brodie\" Department of Neuroscience, University of Cagliari, Cagliari, Italy; \"G. Fontana\" Center for the Study and Treatment of Alcohol Addiction, University of Bologna, Bologna, Italy; C.N.R. Institute of Neuroscience, Section of Cagliari, Cagliari, Italy. (literal)
Titolo
  • Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam (literal)
Abstract
  • BACKGROUND AND PURPOSE: Benzodiazepines are the drugs of choice in treatment of alcohol withdrawal syndrome (AWS). Recent data have shown that baclofen may reduce AWS symptoms. At present no comparative studies between baclofen and any benzodiazepine used in AWS treatment are available. Accordingly, the present study was designed to compare efficacy, tolerability and safety of baclofen vs diazepam in the treatment of AWS. SUBJECTS AND METHODS: Thirty-seven patients with AWS were enrolled in the study and randomly divided into two groups. Baclofen (30 mg/die for 10 consecutive days) was orally administered to 18 patients (15 males, 3 females; median age: 46.5). Diazepam (0.5-0.75 mg/kg/die for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10) was orally administered to 19 patients (17 men, 2 women; median age: 42.0 years). The Clinical Institute Withdrawal Assessment (CIWA-Ar) was used to evaluate physical symptoms of AWS. RESULTS: Both baclofen and diazepam significantly decreased CIWA-Ar score, without significant differences between the two treatments. When CIWA-Ar subscales for sweating, tremors, anxiety and agitation were evaluated singly, treatment with baclofen and diazepam resulted in a significant decrease in sweating, tremors and anxiety score, without significant differences between the two drug treatments. Both treatments decreased the agitation score, although diazepam was slightly more rapid than baclofen. CONCLUSION: The efficacy of baclofen in treatment of uncomplicated AWS is comparable to that of the \"gold standard\" diazepam. These results suggest that baclofen may be considered as a new drug for treatment of uncomplicated AWS. (literal)
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Autore CNR di
Prodotto
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it